InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.450 0.04 (9.76%)+
Announcement
Release
7 Jan 2026 9:44AM
Price at Release
$0.410
Full Release
download
Summary
Island Pharmaceuticals Limited announced the granting of US Patent Number 12,508,266 for the antiviral drug Galidesivir, extending intellectual property protection until October 2031. This patent covers the treatment of filoviridae viruses, including Ebola and Marburg, which are recognized as significant public health threats. The patent is a strategic move to support Island Pharmaceuticals' clinical development plans for Galidesivir, a molecule active against a wide range of RNA viruses. This development reinforces the company's focus on unmet medical needs related to urgent viral diseases and biosecurity threats.
Key Points
  • US Patent Number 12,508,266 granted for the use of Galidesivir in treating filoviridae viruses.
  • Patent protection is provided through October 2031.
  • This patent includes claims for treating viruses like Marburg and Ebola.
  • The patent aligns with Island Pharmaceuticals' clinical development strategy for Galidesivir.
  • Galidesivir is an antiviral molecule with broad-spectrum activity against over 20 RNA viruses.
  • Filoviridae viruses are classified as biological select agents posing severe public health risks.
  • Island Pharmaceuticals focuses on drugs addressing urgent viral diseases and biosecurity threats.
  • The patent is part of a broader strategy to expand Island Pharmaceuticals' intellectual property.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.